CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02530437
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:05.034074+00:00
Published At: 2023-07-10T00:00:00+00:00
Record Updated At: 2023-07-10
Results Posted At: 2023-07-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Gastroesophageal Junction Adenocarcinoma", "Stage IB Esophageal Adenocarcinoma AJCC v7", "Stage II Esophageal Adenocarcinoma AJCC v7", "Stage IIA Esophageal Adenocarcinoma AJCC v7", "Stage IIB Esophageal Adenocarcinoma AJCC v7", "Stage IIIA Esophageal Adenocarcinoma AJCC v7", "Stage IIIB Esophageal Adenocarcinoma AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-07-10"
protocolSection.identificationModule.nctId: "NCT02530437"
protocolSection.identificationModule.officialTitle: "A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-07-10"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.